new service selector

We suggest customising the BASIC NephroTox Study This service provides unparalleled assessment of renal toxicity in human, mouse, rat or dog thanks to the use of our uniquely predictive aProximateTM model. Cellular viability is determined by quantifying ATP and LDH levels and by measuring trans-epithelial electrical resistance (TEER). Gene analysis, inhibitor study and species comparison (human, mouse, rat and dog) are available as insightful complements.

The detection of early and late toxic effects is made possible by exploiting the properties of this fully differentiated primary in vitro proximal tubule cells model that closely mimicks renal transport with high expression of all relevant basolateral and apical transporters involved in drug handling, including megalin and cubilin, and expression of clinically relevant biomarkers of toxicity including KIM-1, NGAL and Clusterin. Our experts and regular supply of fresh tissue, will rapidly provide you with predictive data to give you high confidence for key decision making, accelerating your pipeline development.

We suggest customising our COMPREHENSIVE NephroTox Study This in-depth study provides unparalleled assessment of renal toxicity in human, mouse, rat or dog thanks to the use of our uniquely predictive aProximateTTM model. In this comprehensive service, cellular viability is determined by quantifying ATP and LDH levels and by measuring trans-epithelial electrical resistance (TEER). FDA-approved kidney injury markers NGAL, KIM1 and Clusterin are quantified as part of this service, ensuring your IND submissions will be further strengthened by the testing of parameters and biomarkers that follow regulatory guidelines. Gene analysis, inhibitor study and species comparison (human, mouse, rat and dog) are available as insightful complements.

The detection of early and late toxic effects is made possible by exploiting the properties of this fully differentiated primary in vitro proximal tubule cells model that closely mimicks renal transport with high expression of all relevant basolateral and apical transporters involved in drug handling, including megalin and cubilin, and expression of clinically relevant biomarkers of toxicity including KIM-1, NGAL and Clusterin. Our experts and regular supply of fresh tissue, will rapidly provide you with predictive data to give you high confidence for key decision making, accelerating your pipeline development.

We suggest talking to our team of experts about how we can answer your query by developing a fully customised set of experiments on our fully differentiated aProximateTM primary in vitro proximal tubule cells model to provide you with predictive data to progress your compound. The aProximate model closely mimics renal transport with high expression of all relevant basolateral and apical transporters and expression of clinically relevant biomarkers of toxicity.

We suggest talking to our team of experts about how we can answer your query by developing a fully customised set of experiments on our fully differentiated aProximateTM primary in vitro proximal tubule cells model to provide you with predictive data to progress your compound. The aProximate model closely mimics renal transport with high expression of all relevant basolateral and apical transporters and expression of clinically relevant biomarkers of toxicity.

We suggest customising the Compound Functional/Efficacy study This quick turnaround service provides predictive data about the renal flux of your compound in the proximal tubule cells, including the measurement of Jab, Jba, Jnet, intracellular accumulation and paracellular flux. The assays are carried out on primary, fully differentiated proximal tubule cells with high expression of all relevant basolateral and apical transporters involved in drug handling, thus giving you high confidence for key decision making and significantly accelerating your pipeline development or your IND submission.

We suggest customising the Compound Uptake Study This service allows you to rapidly assess intra-cellular accumulation of novel drugs in the human, rat, mouse or dog kidney nephron. DDI/inhibitor study and species comparison are available as insightful complements to define the most appropriate species to use or to explain in vivo data. Exploiting the fully differentiated primary proximal tubule cells model with high apical and basal renal transporter expression, intracellular accumulation of your drugs will be accurately quantified. Our experts will tailor the experiments to deliver a set of predictive data for key decision making, significantly accelerating your pipeline development.

We suggest customising our Retina Efficacy Study This study is usually completed within two months, accelerating your pipeline development or your IND submission. It will be carried out on our highly reproducible and readily available iPSC-derived human organoids and/or RPE models that recapitulate the native human tissues in structure and function. The Retina Efficacy Study will deliver morphological characterisation by brightfield imaging as well as qualitative and quantitative key expression marker analysis by immunofluorescence, gene expression and TEM/SEM (if relevant). Additional functional readouts of trans-epithelial resistance (TEER) measurements and phagocytosis of photoreceptor outer segment can be provided for RPE. Our experts will tailor the experiments to rapidly assess the efficacy of your drugs on healthy or disease human retinal models, delivering a complete set of predictive data.

We suggest customising our Gene Therapy Vector Assessment Study This study allows you to rapidly assess and compare the efficacy of novel gene therapy vectors in vitro using highly reproducible and readily available iPSC-derived human organoids and/or RPE models that recapitulate the native human tissues in structure and function. Our experts will tailor the experiments to give you an extensive set of predictive data including transduction efficiency and identification of the target cells within the organoids. The results are usually delivered within two months, saving you precious time in comparison to in vivo and ex vivo experiments. The readouts for this study on RPE and retinal organoids comprise of transduction efficiency of the viral vector, cell viability assessment and determination of therapy efficacy. Cell tropism identification is also included for studies on retinal organoids.

We suggest talking to our team of experts about how we can answer your query by developing a fully customised set of experiments on our highly reproducible and readily available iPSC-derived human organoids and/or RPE models that recapitulate the native human tissues in structure and function.

We suggest customising our COMPREHENSIVE Retina Tox Study This study is usually completed within two months, enabling you to rapidly make a decision on the progress of your new drug or submit your IND. It will be carried out using our highly reproducible and readily available human iPSC derived organoids and/or RPE models that are known to respond to toxins and recapitulate the native tissues in structure and function. The comprehensive study carried out on the RPE model will provide morphological characterisation by brightfield imaging, cell viability assays, flow cytometry analysis, trans-epithelial electrical resistance (TEER) measurements and phagocytosis of photoreceptor outer segment. If the study is carried out on retinal organoids, the outputs include morphological characterisation by brightfield imaging, cell viability assays, flow cytometry analysis as well as qualitative and quantitative key expression markers analysis at protein and RNA level. Our experts will tailor the experiments to give you an extensive set of predictive data relating to the safety and toxicity of your drug.